Most ircAEs responded to symptom- and phenotype-directed dermatologic therapies, whereas biologic therapies were effective in patients with corticosteroid-refractory disease. Increased eosinophils, IL-6, IL-10, and immunoglobulin E were associated with ircAEs, and they may represent actionable therapeutic targets for immune-related skin toxicities.
No takes yet. Share an insight, caveat, or question.
Phillips et al. (2019) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: